Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04567745 · ClinicalTrials.gov registry record · Phase 1
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
A Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04567745 is a Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by Mayo Clinic. The registered enrollment target is 80 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04567745, a Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to provide clinical validation of EyeQuant, a fully automated retinal image analysis system for computation of vascular biomarkers indicative of cognitive disorders, using retinal fundus photographs collected from patients with mild cognitive impairment, Alzheimer's disease, and vascular dementia.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Retinal fundus photography
Study Locations (1)
Arizona
- Mayo Clinic Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04567745
The ClinicalTrials.gov registry entry for NCT04567745 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Retinal fundus photography is the first listed.
NCT04567745 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT04567745 about?
NCT04567745 is a clinical study titled "Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers". This study aims to provide clinical validation of EyeQuant, a fully automated retinal image analysis system for computation of vascular biomarkers indicative of cognitive disorders, using retinal fundus photographs collected from patients with mild cognitive impairment, Alzheimer's disease, and vasc...
What is the current status of trial NCT04567745?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2020-09-29. Estimated completion is 2021-09-30.
What conditions does trial NCT04567745 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia.
What interventions are being tested in trial NCT04567745?
The interventions under investigation include: Retinal fundus photography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04567745?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04567745 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.